Immature Beta Cell Differentiation via NGN3 Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to efficiently differentiate pluripotent stem cells into mature and functional pancreatic β-cells in vitro due to discrepancies in marker expression timing compared to in vivo mammalian development, and existing protocols require long maturation times for pancreatic endoderm cell populations upon implantation.
Innovation Solution
A method involving contacting definitive endoderm lineage cells with TGFβ superfamily growth factors and Wnt family members, such as Activin A and Wnt3a, to generate PDX1-positive pancreatic endoderm cells, while suppressing NGN3 expression, thereby enriching for non-endocrine multipotent pancreatic progenitor cells (CHGA-), which can differentiate into insulin-producing β-cells both in vitro and in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional differentiation protocols are used to generate pancreatic endoderm cells, then cell populations are generated, but the maturation time in vivo is long (8-12 weeks) and β-cell function is not efficiently achieved
Solution Approach 1:
The protocol performs preliminary actions by suppressing NGN3 expression during early stages and delaying endocrine marker expression until after non-endocrine multipotent pancreatic progenitor differentiation is established. This preliminary suppression of endocrine commitment allows cells to first establish a progenitor state that is primed for subsequent β-cell maturation, thereby reducing in vivo maturation time
Solution Approach 2:
The invention changes key differentiation parameters by modifying the timing and expression levels of transcription factors (NGN3 suppression, PDX1/NKX6.1 co-expression). These parameter changes shift the differentiation trajectory to favor non-endocrine multipotent progenitor cells that are more efficient at maturing into functional β-cells in vivo
2Reliability
If pluripotent stem cells are differentiated using traditional protocols, then pancreatic endoderm cells are produced, but marker expression timing does not match in vivo mammalian development
Solution Approach 1:
The protocol inverts the traditional differentiation sequence by suppressing NGN3 (an early endocrine marker) and delaying other endocrine markers until after non-endocrine progenitor differentiation. This inverted approach better mimics in vivo development where non-endocrine progenitors are established before endocrine commitment, thereby improving manufacturing precision of marker expression timing
Solution Approach 2:
The invention changes the parameter of marker expression timing by suppressing NGN3 during early stages and inducing PDX1/NKX6.1 co-expression at specific time points. These parameter changes align in vitro differentiation with in vivo developmental timing, improving both reliability and precision
3Quantity of substance
If PEC populations contain more cells committed to endocrine lineage (CHGA+), then endocrine cell production increases, but the percentage of non-endocrine multipotent pancreatic progenitor cells (CHGA-) that mature into β-cells decreases
Solution Approach 1:
The protocol performs preliminary suppression of endocrine commitment markers (NGN3, CHGA) during early differentiation stages. This preliminary action ensures that cells first establish a non-endocrine multipotent progenitor state before any endocrine commitment occurs, maximizing the proportion of cells that can efficiently mature into β-cells while still producing sufficient endocrine cells
Data Source
AI summary
A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.